Mar 20, 2020
Antihypertensive Drugs Industry Outlook to 2027 by Drug, Condition, Medication Type, Distribution Channel and Region
Jan 15, 2020
Antihypertensive Drugs Market to Garner $28.79 Bn, Globally, by 2026 at 3.1% CAGR, Says Allied Market Research
Nov 17, 2019
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Sep 02, 2019
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
Mar 19, 2019
The antihypertensive drugs market will register a CAGR of over 2% by 2023
Mar 14, 2019
Arbor Pharmaceuticals Teams Up with Shaquille O'Neal to Help African Americans 'Get Real' About Heart Failure
Mar 09, 2019
Information Update - Multiple Losartan-containing drugs voluntarily recalled because of potential for nitrosamine impurity
Jan 11, 2019
Bernstein Liebhard LLP Evaluating Potential Valsartan Lawsuits for Cancer and Liver Injuries Allegedly Caused by Contaminated Heart and Blood Pressure Medications
Nov 16, 2018
Sollis Therapeutics Announces the First Patient Enrolled in a Phase 3 Clinical Trial of Clonidine Micropellet for Sciatica
Nov 11, 2018
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
Nov 08, 2018
Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)
Jul 13, 2018
FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity
Jul 10, 2018
Update - Advisory - Several drugs containing valsartan being recalled due to contamination with a potential carcinogen
Jul 09, 2018
Advisory - Several drugs containing valsartan being recalled due to contamination with a potential carcinogen
Jun 06, 2018
Daiichi Sankyo's U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In
May 28, 2018
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
Nov 15, 2017
Noden Pharma Announces FDA Approval of Tekturna®(aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
Sep 19, 2017
New analysis shows Entresto improved physical and social activity in patients with HFrEF
Aug 01, 2017
Daiichi Sankyo Announces Settlement Agreement on U.S. Products Liability Litigation